GYRE
Income statement / Annual
Last year (2024), Gyre Therapeutics, Inc.'s total revenue was $105.76 M,
a decrease of 6.78% from the previous year.
In 2024, Gyre Therapeutics, Inc.'s net income was $12.09 M.
See Gyre Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$105.76 M |
$113.45 M |
$102.29 M |
$7.34 M |
$20.95 M |
$0.00 |
$6.00 K |
$1.02 M |
$399.00 K |
$1.75 M |
| Cost of Revenue |
$3.88 M
|
$4.64 M
|
$4.79 M
|
$7.67 M
|
$9.16 M
|
$146.00 K
|
$21.47 M
|
$12.85 M
|
$10.56 M
|
$5.96 M
|
| Gross Profit |
$101.87 M
|
$108.81 M
|
$97.50 M
|
-$332.00 K
|
$11.79 M
|
-$146.00 K
|
-$21.47 M
|
-$11.83 M
|
-$10.16 M
|
-$4.21 M
|
| Gross Profit Ratio |
0.96
|
0.96
|
0.95
|
-0.05
|
0.56
|
0
|
-3578
|
-11.62
|
-25.45
|
-2.4
|
| Research and Development Expenses |
$12.02 M
|
$13.78 M
|
$16.69 M
|
$64.57 M
|
$52.98 M
|
$43.86 M
|
$21.47 M
|
$12.85 M
|
$11.56 M
|
$5.96 M
|
| General & Administrative Expenses |
$16.11 M
|
$14.66 M
|
$17.37 M
|
$0.00
|
$16.18 M
|
$0.00
|
$12.35 M
|
$9.99 M
|
$9.26 M
|
$9.59 M
|
| Selling & Marketing Expenses |
$57.51 M
|
$61.16 M
|
$54.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$73.62 M
|
$75.82 M
|
$71.61 M
|
$18.82 M
|
$16.18 M
|
$13.27 M
|
$12.35 M
|
$9.99 M
|
$9.26 M
|
$9.59 M
|
| Other Expenses |
$66.00 K
|
$86.44 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.65 M
|
$261.00 K
|
$86.00 K
|
$0.00
|
| Operating Expenses |
$85.71 M
|
$176.04 M
|
$88.29 M
|
$83.39 M
|
$69.16 M
|
$57.13 M
|
$33.83 M
|
$22.84 M
|
$20.82 M
|
$15.55 M
|
| Cost And Expenses |
$89.59 M
|
$180.68 M
|
$93.09 M
|
$91.06 M
|
$78.32 M
|
$57.28 M
|
$33.83 M
|
$22.84 M
|
$20.82 M
|
$15.55 M
|
| Interest Income |
$1.55 M
|
$1.04 M
|
$726.00 K
|
$39.00 K
|
$561.00 K
|
$2.15 M
|
$3.77 M
|
$261.00 K
|
$3.47 M
|
$518.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.48 M
|
| Depreciation & Amortization |
$1.59 M
|
$1.11 M
|
$1.13 M
|
$290.00 K
|
$138.00 K
|
$146.00 K
|
$149.00 K
|
$173.00 K
|
$389.00 K
|
$470.00 K
|
| EBITDA |
$17.82 M |
$20.33 M |
$10.33 M |
-$87.64 M |
-$56.10 M |
-$55.03 M |
-$33.82 M |
-$21.82 M |
-$16.95 M |
-$12.81 M |
| EBITDA Ratio |
0.17
|
0.18
|
0.1
|
-11.94
|
-2.68
|
0
|
-5637
|
-21.44
|
-42.47
|
-7.32
|
| Operating Income Ratio |
0.15
|
-0.59
|
0.09
|
-11.41
|
-2.74
|
0
|
-5637
|
-21.44
|
-51.17
|
-7.89
|
| Total Other Income/Expenses Net |
$7.06 M
|
-$9.74 M
|
$209.00 K
|
-$4.21 M
|
$1.13 M
|
$2.10 M
|
$3.77 M
|
$261.00 K
|
$3.47 M
|
-$960.00 K
|
| Income Before Tax |
$23.22 M
|
-$76.97 M
|
$9.41 M
|
-$87.93 M
|
-$56.24 M
|
-$55.18 M
|
-$30.06 M
|
-$21.56 M
|
-$16.95 M
|
-$14.76 M
|
| Income Before Tax Ratio |
0.22
|
-0.68
|
0.09
|
-11.98
|
-2.68
|
0
|
-5009.17
|
-21.18
|
-42.47
|
-8.44
|
| Income Tax Expense |
$5.32 M
|
$8.52 M
|
$5.10 M
|
$0.00
|
-$699.00 K
|
$0.00
|
$0.00
|
-$173.00 K
|
$0.00
|
$0.00
|
| Net Income |
$12.09 M
|
-$92.93 M
|
$2.30 M
|
-$87.93 M
|
-$55.54 M
|
-$55.18 M
|
-$30.06 M
|
-$21.56 M
|
-$16.95 M
|
-$14.76 M
|
| Net Income Ratio |
0.11
|
-0.82
|
0.02
|
-11.98
|
-2.65
|
0
|
-5009.17
|
-21.18
|
-42.47
|
-8.44
|
| EPS |
0.14 |
-1.41 |
0.0301 |
-2.87 |
-2.93 |
-4.41 |
-2.68 |
-6.3 |
-21.76 |
-49.99 |
| EPS Diluted |
0.05 |
-1.41 |
0.03 |
-2.87 |
-2.93 |
-4.41 |
-2.68 |
-6.3 |
-21.76 |
-49.99 |
| Weighted Average Shares Out |
$85.09 M
|
$65.83 M
|
$76.74 M
|
$30.64 M
|
$19.18 M
|
$12.00 M
|
$11.21 M
|
$3.42 M
|
$778.78 K
|
$295.27 K
|
| Weighted Average Shares Out Diluted |
$102.29 M
|
$65.83 M
|
$75.69 M
|
$30.64 M
|
$19.18 M
|
$12.00 M
|
$11.21 M
|
$3.42 M
|
$778.78 K
|
$295.27 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
